# N-(p-Coumaroyl) Serotonin Ameliorates LPS-Induced Inflammation in BV2 Microglia via MAPK/NF-κB Inactivation and HO-1/NQO1 Upregulation

**Authors:** Chang Hyeon Jeon, Soo-Jin Park, Seok Han Yun, Hyun-Jae Jang, Mun-Ock Kim, Jae-Won Lee

PMC · DOI: 10.3390/cimb48020232 · 2026-02-21

## TL;DR

N-(p-Coumaroyl) serotonin reduces inflammation in microglial cells by blocking harmful signaling pathways and boosting protective antioxidant systems.

## Contribution

This study identifies a novel anti-inflammatory mechanism of N-(p-coumaroyl) serotonin in microglia via MAPK/NF-κB suppression and HO-1/NQO1 activation.

## Key findings

- CS pretreatment reduced inflammatory cytokines IL-6, TNF-α, and MCP-1 in LPS-challenged microglia.
- CS inhibited iNOS and COX-2 protein levels through MAPK/NF-κB pathway disruption.
- CS activated HO-1/NQO1 and interfered with TLR4/MyD88 signaling to exert antioxidant effects.

## Abstract

Uncontrolled inflammation contributes to the development of neurodegenerative diseases (NDs) like Alzheimer’s disease (AD). N-(p-Coumaroyl) serotonin (CS) has demonstrated a significant capacity to modulate hyper-inflammation. We explored whether CS could mitigate inflammatory responses in endotoxin-challenged microglial cells and sought to elucidate the specific molecular mechanisms governing these effects. ELISA, nitric oxide (NO) assays, Western blotting and immunocytochemistry were performed to study inflammatory responses and related signal transduction mechanisms. CS pretreatment effectively attenuated the inflammatory output in endotoxin-primed microglial models. This was evidenced by a significant reduction in key cytokines (such as IL-6, TNF-α, and MCP-1) and a concomitant decrease in the protein levels of iNOS and COX-2. These effects were mediated through the disruption of MAPK/NF-κB signaling cascades and the sequestration of NF-κB within the cytoplasm. Beyond its anti-inflammatory role, CS promoted the HO-1/NQO1 signaling pathway and interfered with the LPS-mediated TLR4/MyD88 cascade. Our collective evidence indicates that the modulation of microglia-mediated inflammation by CS is underpinned by the suppression of MAPK/NF-κB and the induction of antioxidant systems, suggesting that CS may have the potential to improve NDs.

## Linked entities

- **Proteins:** IL6 (interleukin 6), TNF (tumor necrosis factor), CCL2 (C-C motif chemokine ligand 2), NOS2 (nitric oxide synthase 2), COX2 (cytochrome c oxidase subunit II), NFKB1 (nuclear factor kappa B subunit 1), HMOX1 (heme oxygenase 1), NQO1 (NAD(P)H quinone dehydrogenase 1), TLR4 (toll like receptor 4), MYD88 (MYD88 innate immune signal transduction adaptor)
- **Chemicals:** N-(p-Coumaroyl) serotonin (PubChem CID 340063), doxorubicin (PubChem CID 31703)
- **Diseases:** Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, ISYNA1 (inositol-3-phosphate synthase 1) [NCBI Gene 51477] {aka INO1, INOS, IPS, IPS 1, IPS-1}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, Rela (Rela proto-oncogene, NFKB subunit) [NCBI Gene 19697] {aka p65, p65 NF-kappa B, p65 NFkB}, Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 19225] {aka COX2, Cox-2, PES-2, PGHS-2, PHS II, PHS-2}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, Mapk8 (mitogen-activated protein kinase 8) [NCBI Gene 26419] {aka JNK, JNK1, Prkm8, SAPK1}, NQO1 (NAD(P)H quinone dehydrogenase 1) [NCBI Gene 1728] {aka DHQU, DIA4, DTD, NMOR1, NMORI, QR1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Ccl2 (C-C motif chemokine ligand 2) [NCBI Gene 20296] {aka HC11, JE, MCAF, MCP-1, MCP1, SMC-CF}, Nqo1 (NAD(P)H dehydrogenase, quinone 1) [NCBI Gene 18104] {aka Dia4, Dtd, Nmo-1, Nmo1, Nmor1, Ox-1}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, Hmox1 (heme oxygenase 1) [NCBI Gene 15368] {aka D8Wsu38e, HO-1, HO1, Hemox, Hmox, Hsp32}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 17709], Myd88 (myeloid differentiation primary response gene 88) [NCBI Gene 17874], Nfkbia (nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha) [NCBI Gene 18035] {aka Nfkbi}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}
- **Diseases:** atherosclerotic (MESH:D050197), infection (MESH:D007239), cytotoxicity (MESH:D064420), mammary carcinoma (MESH:D001943), inflammatory cytokines (MESH:D000080424), neuronal damage (MESH:D009410), glioblastoma (MESH:D005909), hyper (MESH:D007589), cognitive decline (MESH:D003072), CS (MESH:D020230), NDs (MESH:D019636), injury to (MESH:D014947), Inflammation (MESH:D007249), epileptic condition (MESH:D020763), PD (MESH:D010300), ND (MESH:C537849), AD (MESH:D000544), neurotoxic (MESH:D020258), neuroinflammation (MESH:D000090862), seizure (MESH:D012640)
- **Chemicals:** CS (MESH:C114774), BCA (-), sulfanilamide (MESH:D000077145), phosphoric acid (MESH:C030242), Nitrite (MESH:D009573), MTT (MESH:C070243), Alexa Fluor 488 (MESH:C000711379), CO2 (MESH:D002245), polyphenol (MESH:D059808), LPS (MESH:D008070), PVDF (MESH:C024865), PBS (MESH:D007854), dopaminergic (MESH:D004298), serotonin (MESH:D012701), formalin (MESH:D005557), DMSO (MESH:D004121), DAPI (MESH:C007293), formazan (MESH:D005562), Triton X-100 (MESH:D017830), PGE2 (MESH:D015232), Griess reagent (MESH:C095000), SDS (MESH:D012967), NO (MESH:D009569)
- **Species:** Homo sapiens (human, species) [taxon 9606], Escherichia coli O26 (serogroup) [taxon 404399], Mus musculus (house mouse, species) [taxon 10090], Carthamus tinctorius (safflower, species) [taxon 4222]
- **Cell lines:** BV-2 — Mus musculus (Mouse), Transformed cell line (CVCL_0182), LM001-05 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_W876)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939688/full.md

---
Source: https://tomesphere.com/paper/PMC12939688